Inappropriately overriding EHR alerts leads to a 6-fold increase in adverse drug events

Inappropriately overriding clinical decision support (CDS) in electronic health records (EHRs) was linked to a six-time increase in adverse drug events (ADEs), according to a study published Feb. 9 in BMJ Quality and Safety.

 

CDS in EHRs is meant to reduce medication errors and ADEs, but these alerts are often overridden in an inappropriate manner and could cause harm to patients. In this study, researchers from Brigham and Women’s Hospital evaluated the potential harm linked to CDS overrides in patients in the ICU.

Adults admitted to any of six ICUs from July 2016 to April 2017 at Brigham were analyzed for the study. Patients with provider-overridden CDS for dose, drug allergy, drug–drug interaction, geriatric and renal alerts were included.

Overall, a total of 2,448 override alerts were collected from 712 patient encounters. Results showed an 81.6 percent appropriateness rate for overrides. More ADEs followed inappropriate overrides compared to those that were appropriate. Inappropriate overrides were found to be linked to a six time increase in potential and definite ADEs when compared to appropriate overrides.

“Approximately four of five identified CDS overrides were appropriately overridden, though the rate varied substantially by alert type,” concluded first author Adrian Wong and colleagues. “Inappropriate overrides were six times as likely to be associated with an ADE (potential and definite) compared with appropriate overrides, confirming that decision support can identify clinically important situations. Further efforts should be targeted at improving the positive predictive value of CDS in a number of ways, including by following human factor principles in alert presentation, by suppressing alerts that are appropriately overridden, by using clinical information about individual patients to improve the likelihood that the alerts will be appropriate and by using techniques such as artificial intelligence to help determine which alerts to present.”

""
Cara Livernois, News Writer

Cara joined TriMed Media in 2016 and is currently a Senior Writer for Clinical Innovation & Technology. Originating from Detroit, Michigan, she holds a Bachelors in Health Communications from Grand Valley State University.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.